Payment overview · 2025
General Payments
$3,496.55
76 reported records · 21 companies
Healthcare provider profile · identity verified
Basel Kasabali, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SHREVEPORT, LA · NPI 1417921123
Verified facts
What the public records show
CMS Open Payments records show Basel Kasabali, MD received $3,496.55 in general payments during 2025 across 76 reported records.
Abbott Laboratories accounted for 42.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 767 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 458 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 767 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,472.97 | 42.1% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$731.98 | 20.9% | 7 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $196.85 | 5.6% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $165.56 | 4.7% | 13 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $159.45 | 4.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $131.08 | 3.8% | 8 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $104.07 | 3.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $100.96 | 2.9% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $57.97 | 1.7% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $53.10 | 1.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.64 | 1.5% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $44.88 | 1.3% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $40.31 | 1.1% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.26 | 1.1% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $39.68 | 1.1% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $21.93 | 0.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.65 | 0.5% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $16.39 | 0.5% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.34 | 0.5% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $16.10 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,869.23 | 8 |
| Food and Beverage | $1,627.32 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $1,453.43 | 10 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $159.45 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.33 | 7 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $104.07 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $61.26 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $61.26 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $52.64 | 3 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $43.90 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $40.31 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $39.68 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $36.77 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $35.07 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $28.73 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $10.93 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $10.13 | 2 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $9.86 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $7.55 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $6.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 767 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 458 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
767 | 146 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
458 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
767 | 146 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 767 | 146 |
| Clopidogrel | Clopidogrel Bisulfate | 539 | 134 |
| Entresto | Sacubitril/Valsartan | 458 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 440 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 115 |
| Carvedilol | Carvedilol | 352 | 92 |
| Hydralazine Hcl | Hydralazine Hcl | 311 | 79 |
| Furosemide | Furosemide | 310 | 97 |
| Sotalol | Sotalol Hcl | 292 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 76 |
| Amiodarone Hcl | Amiodarone Hcl | 286 | 88 |
| Digoxin | Digoxin | 267 | 63 |
| Losartan Potassium | Losartan Potassium | 255 | 77 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 242 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 60 |
| Ranolazine Er | Ranolazine | 210 | 53 |
| Propafenone Hcl | Propafenone Hcl | 209 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 64 |
| Nebivolol Hcl | Nebivolol Hcl | 160 | 40 |
| Dofetilide | Dofetilide | 139 | 22 |
| Lisinopril | Lisinopril | 124 | 29 |
| Potassium Chloride | Potassium Chloride | 122 | 33 |
| Bumetanide | Bumetanide | 90 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 88 | 34 |
| Nifedipine Er | Nifedipine | 79 | 18 |
| Amoxicillin | Amoxicillin | 77 | 62 |
| Brilinta | Ticagrelor | 75 | 13 |
| Xarelto | Rivaroxaban | 74 | 18 |
| Spironolactone | Spironolactone | 72 | 27 |
| Farxiga | Dapagliflozin Propanediol | 71 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 50 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 14 |
| Corlanor | Ivabradine Hcl | 50 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | 17 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | 11 |
| Dilt-Xr | Diltiazem Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 15 |
| Midodrine Hcl | Midodrine Hcl | 36 | 11 |
| Multaq | Dronedarone Hcl | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 26 |
| Cartia Xt | Diltiazem Hcl | 33 | 13 |
| Metolazone | Metolazone | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | 12 |
| Mexiletine Hcl | Mexiletine Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Colchicine | Colchicine | 18 | 18 |
| Prednisone | Prednisone | 17 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Ivabradine Hcl | Ivabradine Hcl | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,496.55 · 76 records | Abbott Laboratories | ANGIO-SEAL, AURORA EV-ICD MRI SURESCAN, AVEIR, AVVIGO Guidance System, Assure WCD, BodyGuardian, CAMZYOS, COBALT DR MRI SURESCAN, CT THROMBECTOMY SYSTEM KIT, ECC Solutions, ELIQUIS, ELUVIA, EMBLEM MRI S-ICD, ENTRESTO, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EkoSonic, FARAPULSE, FLOWTRIEVER CATHETER, S, GORE VIABAHN Endoprosthesis with Heparin, General - CRM_CRM, General - EP, INSPIRE, JETSTREAM SC, LEQVIO, LifeVest, MCOT, PULSESELECT, Paradise Ultrasound Renal Denervation System, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, VERQUVO, WatchPATONE, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error